Uploaded May 2025 | Updated September 2026, 2 weeks ago
Welcome to another insightful episode of #ExpertTalk by EverythingALS!
In this EverythingALS expert session, Dr. Merit Cudkowicz, a leading ALS researcher and Director of the Healey Center for ALS, answers some of the most pressing questions from the ALS community. From biomarkers to drug trials, she shares expert insights into where ALS research is headed — and what patients and families can expect.
What You’ll Learn in This Episode:
In this episode, Dr. Merit Cudkowicz shares expert insights on the latest in ALS research, including promising therapies like Spinogenix SPG302 and IL-2, the role of PET scans in detecting neuroinflammation, and why some ALS patients maintain normal NFL levels. She also addresses access issues around treatments like methylcobalamin and discusses how adaptive platform trials are reshaping the path to FDA approvals.
Timestamps:
00:57:00 – Welcome & Introductions
01:03:55 – New Therapies: Spinogenix SPG302 & IL-2 in MIRACALS Study
01:40:12 – Access to Vitamin B12 (Methylcobalamin) in Canada
01:46:27 – Role of PET Scans in Diagnosing Neuroinflammation
01:55:32 – FDA Approval Timelines for ALS Drugs
01:59:00 – Normal NFL Levels in Some ALS Patients
Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals
#ExpertTalk #EverythingALS #ALSResearch #ALSResearch
#DrMeritCudkowicz #NeurodegenerativeDiseases #Spinogenix #Methylcobalamin #IL2Therapy #PETScan #FDAApproval #PlatformTrials #HealeyALSPlatform #ALSCommunity #Neurofilament #ALSProgress #ClinicalTrials
If you’re interested in the latest developments in ALS research and treatment, hit the like button, subscribe, and turn on notifications for future updates. Share this video with others who may benefit from this essential information.
Welcome to another insightful episode of #ExpertTalk by EverythingALS!
In this EverythingALS expert session, Dr. Merit Cudkowicz, a leading ALS researcher and Director of the Healey Center for ALS, answers some of the most pressing questions from the ALS community. From biomarkers to drug trials, she shares expert insights into where ALS research is headed — and what patients and families can expect.
What You’ll Learn in This Episode:
In this episode, Dr. Merit Cudkowicz shares expert insights on the latest in ALS research, including promising therapies like Spinogenix SPG302 and IL-2, the role of PET scans in detecting neuroinflammation, and why some ALS patients maintain normal NFL levels. She also addresses access issues around treatments like methylcobalamin and discusses how adaptive platform trials are reshaping the path to FDA approvals.
Timestamps:
00:57:00 – Welcome & Introductions
01:03:55 – New Therapies: Spinogenix SPG302 & IL-2 in MIRACALS Study
01:40:12 – Access to Vitamin B12 (Methylcobalamin) in Canada
01:46:27 – Role of PET Scans in Diagnosing Neuroinflammation
01:55:32 – FDA Approval Timelines for ALS Drugs
01:59:00 – Normal NFL Levels in Some ALS Patients
Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals
#ExpertTalk #EverythingALS #ALSResearch #ALSResearch
#DrMeritCudkowicz #NeurodegenerativeDiseases #Spinogenix #Methylcobalamin #IL2Therapy #PETScan #FDAApproval #PlatformTrials #HealeyALSPlatform #ALSCommunity #Neurofilament #ALSProgress #ClinicalTrials
If you’re interested in the latest developments in ALS research and treatment, hit the like button, subscribe, and turn on notifications for future updates. Share this video with others who may benefit from this essential information.
